Pfizer, Inc. Increases Dividend By 7% to 30 Cents.

America's largest healthcare company has planned on increasing its dividend by 7% in efforts to keep its shareholders happy.

In an attempt to move its business to a low-tax jurisdiction, Pfizer, Inc. has decided to merge with Allergan PLC in a $1.6 billion bid. Many believe that this merger is one of the biggest tax inversion deals in the history so far due to which it has managed to receive a lot of criticism from the US politicians.

Presently company’s on their foreign income pay income tax of 35% because of which the United States based companies mostly end up paying double tax on their foreign income. This attempt of parking their foreign income overseas many companies has started to take this route of settling their core business outside of the country.

In 2013, the pharmaceutical corporation, Pfizer managed to earn $17 billion on its foreign sales which make up 80% of the sales in the United States. While on the other hand, when internationally the pharma company was making billions, in the United States it was incurring losses for five consecutive years.

The chief executive officer of the pharma company Ian Read has continuously called the tax system of the country “hugely disadvantageous” when it comes to competing with international healthcare companies.

Pfizer stock, as of previous trading is up by 0.31% and is now trading at $32.26 in after hour trading sessions. This increase happened after the healthcare company had announced an increase in its quarterly dividends. In the first quarter, the company announced a dividend of 30 cents for each share which showed a 7% increase in its previous dividend price of 28 cents. Ian Read, on the dividend matter, made a statement that this increase in its quarterly dividend is a testament to the company’s continued commitment and working towards enhancing its shareholders value and furthermore, shows how much confidence the company hold in the its business.  

The CEO further added that the pharmaceutical company’s main aim had always been to maximize the shareholder’s returns and the main ingredient to do so is the dividends as they are the main component. The merged companies will be led by the present CEO of Pfizer while the Dublin based, Allergan’s chief executive officer, Brent Saunders will serve as the chief operating officer of both the companies.

As of October 2015, America’s largest pharmaceutical company had reported better than expected earnings results and for its upcoming years has better expectations as the company has clearly benefited a number of new drugs in the market which came from the acquisition of Hospira.

Pfizer, Inc. Stock Analysis

Pfizer's stock has dropped by 1.31%, currently 0.02% shares of the company are owned by insiders while 73.5% are owned by Institutional investors.

On Monday, the shares of Pfizer dropped by 1.31% and traded at a share price of $34.41. The trading session on Monday started off with an initial share price of $33.1, during the course of the event was seen at a higher level of $33.325. While at the lower level, the share price reached up to $32.42.

The trading session on September 21, 2015 ended with a share price of $32.42 with the number of shares increasing at 23,705,054 shares. The pharmaceutical company’s market capital is $202.60 billion. At present, the outstanding shares in the company are 6,167,348,000.

In the short term, a target price estimate of $38.64 has been suggested for the Pfizer’s Stock. The target price is expected to fluctuate between $34 and $51. $51 being at the higher end of the target price and $34 being at the lower end of the target price has been recommended by eleven stock experts.

Pfizer’s stock price is said to vary between these numbers and a standard deviation has been calculated at $5.55. The pharmaceutical company witnessed a one year high share price at $36.46 and a one year low share price at $27.51. The 52-week high in the share prices was observed on July 31, 2015 while a 52-week low was seen on October 16, 2015. In the past one year, the share price has rallied by 8.85%.

The pharmaceutical company has received a rating of Hold in the short term, according to the stock analysts at Zacks, a research firm. The rank given to the shares of the pharmaceutical company by the stock experts at the research firm is 3 while 13 analysts have given an average rating of 1.92. Out of these 13 analysts, majority number of experts (eight) has suggested a Strong Buy on the shares of the company. Four have recommended a Hold rating on the company’s stock, whereas one has given it a rating of Strong Sell.

Insider Buying and Selling Activities information was revealed by the company to the SEC on a Form 4 filing stating that Pfizer’s Senior Vice President Cangialosi Lorettacarried out a transaction on July 30, 2015. According to the information that was provided to the Securities Exchange Commission, the Senior Vice President unloaded 24,704 shares at a share price of $35.65 each. This total transaction was worth $880,698. At present, Pfizer stock news reveals that company insiders own 0.02% of the company’s stock while institutional investors own 73.5%.